Abstract

BackgroundBenzodiazepines are often used as a part of mental health pharmacological management; however, often when prescribed for extended periods, they increase the risk of benzodiazepine use disorder (BUD). Clinical interviews are at the centre of diagnosing this disorder. However, in addition to clinical assessment a simple, validated questionnaire conducted by any healthcare professional may aid in screening for BUD and referral for further management.AimTo compare the accuracy of the severity dependence scale (SDS) as a screening tool for BUD against the standard clinical interviews using the Diagnostic and Statistical Manual of Mental Disorders, edition 5, (DSM 5) checklist amongst benzodiazepine users with primary psychiatric disorders.SettingOutpatient psychiatric clinic in South Rand Hospital, Johannesburg, South Africa.MethodsA cross-sectional study was conducted, once informed consent was attained, looking at demographic and clinical profiles of benzodiazepine users. Clinical interviews were conducted in 81 patients who completed the SDS. In comparing the results of the SDS and clinical interview outcomes, chi-square tests were used to determine an association between categorical variables. A receiver-operating characteristic (ROC) curve was generated in determining the cut-off score in the SDS with the highest sensitivity and specificity.ResultsThis study indicated that a cutoff score of greater than or equal to six of the SDS showed 86% sensitivity and 90.3% specificity compared to a diagnosis of BUD made with clinical interview. The only categorical variables of marginal significance (p~0.06) in comparison to a BUD diagnosis were with benzodiazepine type (oxazepam) and longer duration of use (greater than 24 months).ConclusionThis study identified the SDS as a useful screening tool for BUD with a high sensitivity and specificity compared to interview outcomes. Statistically, correlates were identified between duration and type of benzodiazepine prescribed and BUD suggesting emphasis on these factors when prescribing benzodiazepines.

Highlights

  • Benzodiazepines have been widely used for the treatment of various medical and psychiatric conditions.[1]

  • This was further highlighted by Rowan et al who proposed an increased risk in neurocognitive impairment in people living with HIV (PLWH) who use benzodiazepines.[8]

  • The positive predictive value was 93%, whilst the negative predictive value was 80%

Read more

Summary

Introduction

Benzodiazepines have been widely used for the treatment of various medical and psychiatric conditions.[1] there is no definitive evidence in support of its long-term use considering their side effect profile and issues with dependence.[2,3,4,5,6] Indications for use in psychiatry range from sedation to management of sleep and anxiety.[3,4] regarding these particular indications, research outcomes remain mixed indicating that chronic benzodiazepine use may exacerbate anxiety, sleep and depressive-related symptoms.[5]. Benzodiazepines are often used as a part of mental health pharmacological management; often when prescribed for extended periods, they increase the risk of benzodiazepine use disorder (BUD). In addition to clinical assessment a simple, validated questionnaire conducted by any healthcare professional may aid in screening for BUD and referral for further management

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call